Keyphrases
Second-line Chemotherapy
100%
Prognostic Model
100%
Pancreatic Adenocarcinoma
100%
Overall Survival
66%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
50%
Prognostic Groups
50%
First-line Chemotherapy
33%
First-line Therapy
33%
Albumin Level
33%
Multivariate Analysis
16%
Median Overall Survival
16%
Overall Response Rate
16%
Median Progression-free Survival
16%
Prognostic Factors
16%
Clinical Parameters
16%
Non-responders
16%
Independent Prognostic Factor
16%
Adverse Prognostic Factor
16%
Salvage Chemotherapy
16%
Poor Prognostic
16%
Recurrent or Metastatic
16%
Long-term Survival
16%
Metastatic Pancreatic Ductal Adenocarcinoma
16%
Resectable Pancreatic Cancer
16%
Metastatic Pancreatic Adenocarcinoma
16%
Medicine and Dentistry
Second-Line Chemotherapy
100%
Pancreas Adenocarcinoma
100%
Overall Survival
83%
Prognostic Factor
50%
Oncology
50%
First-Line Chemotherapy
33%
Multivariate Analysis
16%
Progression Free Survival
16%
Pancreas Cancer
16%
Long Term Survival
16%
Chemotherapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Second-Line Chemotherapy
100%
Pancreas Adenocarcinoma
100%
Overall Survival
83%
First-Line Chemotherapy
33%
Progression Free Survival
16%
Chemotherapy
16%
Pancreas Cancer
16%
Long Term Survival
16%